This is the authors' abstract. We don't add key points for this paper.
Specific metabolic markers for early detection of imatinib resistance, including increased glycolytic activity and phospholipid turnover, can be identified in resistant clones. Once validated in human isolated leukocytes, they may be used to monitor the responsiveness of CML patients to treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Klawitter et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: